Light Pharma to help FDA coordinate review, compliance and inspection programs
This article was originally published in The Gold Sheet
Executive Summary
FDA has turned to Light Pharma Inc., the Cambridge, Mass., consulting firm headed by G.K. Raju, to help the agency develop more coordinated interactions between its three drug quality regulatory programs - review, compliance and inspection. A recent evaluation to determine the roles and responsibilities of each program under the regulatory paradigm that is emerging as part of FDA's Pharmaceutical Quality Initiative for the 21st Century "found a lack of clear roles and responsibilities and lack of clear and cohesive process steps for ensuring product quality," FDA said in a solicitation last month. Light Pharma will be following up on that assessment "to develop a seamless process between the various business units involved in product quality review, compliance and inspections with a focus on documenting roles and responsibilities at each stage of the process." The work will include running a pilot test of new standard operating procedures under various scenarios that Light Pharma will develop
You may also be interested in...
FDA Grants and Contracts in Brief
NIPTE gets work under $35 million grant
DRUG RECALL DATA FOR 2000
...show the influence of adverse FDA inspection and sample findings. A majority of recalls conducted recently have been prompted by FDA rather than manufacturer quality systems – a disturbing trend from the agency’s point of view. FDA compliance concerns are reflected, in particular, in a significant number of recalls during 2000 involving the potential for product contamination from faulty aseptic processing and the mishandling of beta-lactam products. Six contamination-related recalls drew a Class I rating as did nine involving products with unapproved claims or ingredients. Error and accident reports shed light on manufacturing problems biologic producers are having, but only a limited percentage result in recalls. [An eight-page tabulation of drug recalls listed in FDA "Enforcement Reports" during 2000 begins on p. 12.]
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.